Head-To-Head Review: Terumo (OTCMKTS:TRUMY) & INLIF (NASDAQ:INLF)

Terumo (OTCMKTS:TRUMY) and INLIF (NASDAQ:INLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Terumo and INLIF, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terumo	0	1	0	0	2.00
INLIF	1	0	0	0	1.00

Risk & Volatility

Terumo has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, INLIF has a beta of 3.47, indicating that its stock price is 247% more volatile than the S&P 500.

Valuation and Earnings

This table compares Terumo and INLIF”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terumo	$6.80 billion	2.87	$772.05 million	$0.58	22.86
INLIF	$18.41 million	0.33	-$5.45 million	N/A	N/A

Terumo has higher revenue and earnings than INLIF.

Profitability

This table compares Terumo and INLIF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Terumo	11.74%	9.01%	6.61%
INLIF	N/A	N/A	N/A

Summary

Terumo beats INLIF on 7 of the 8 factors compared between the two stocks.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

About INLIF

INLIF Ltd. is a holding company, which engages in the development of injection molding machine-dedicated manipulator arms. Its products include: Three-axis robot, Five-axis robot and bull head type manipulator. The company was founded on January 4, 2023 and is headquartered in Quanzhou, China.